Physician profile
Karyn C Markley
NPI 1184728420
$2,258.94
in general payments reported to CMS, 2019-2025
23 companies · $412 in 2025
The $412 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $98.50 · 2021: $599 · 2022: $455 · 2023: $218 · 2024: $295 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.58 | 2019-2022 | |
| Hologic Sales and Service, LLC | $213.64 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Mayne Pharma Commercial LLC | $211.74 | 2021-2025 | |
| Astellas Pharma US INC | $172.00 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $155.52 | 2021-2025 | Slynd |
| Channel Medsystems, INC. | $134.82 | 2022-2023 | |
| Optumhealth Care Solutions, LLC | $107.21 | 2023-2024 | Eitan Medical, Vivify Health Care Team Portal 001, Zyno Solutions |
| Myovant Sciences INC. | $102.39 | 2021-2022 | |
| Pfizer INC. | $100.25 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $82.62 | 2024-2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $66.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.83 | 2019-2025 | |
| Novo Nordisk INC | $40.37 | 2021 | |
| Organon LLC | $31.22 | 2025 | Nexplanon |
| Evofem Biosciences, INC. | $30.26 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $29.73 | 2022 | |
| Amag Pharmaceuticals, INC. | $29.56 | 2019 | |
| Currax Pharmaceuticals LLC | $27.99 | 2020-2021 | |
| Roche Diagnostics Corporation | $23.15 | 2019 | |
| Millicent US INC | $22.29 | 2025 | Intrarosa, Femlyv |
| Medicem INC. | $18.11 | 2021 | |
| Duchesnay USA Incorporated | $17.21 | 2019 | |
| Allergan, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyn Markley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.